These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36029989)

  • 1. Postnatal Foxp2 regulates early psychiatric-like phenotypes and associated molecular alterations in the R6/1 transgenic mouse model of Huntington's disease.
    Rodríguez-Urgellés E; Rodríguez-Navarro I; Ballasch I; Del Toro D; Del Castillo I; Brito V; Alberch J; Giralt A
    Neurobiol Dis; 2022 Oct; 173():105854. PubMed ID: 36029989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of Huntington's Disease-Associated Phenotypes by the Striatum-Enriched Transcription Factor Foxp2.
    Hachigian LJ; Carmona V; Fenster RJ; Kulicke R; Heilbut A; Sittler A; Pereira de Almeida L; Mesirov JP; Gao F; Kolaczyk ED; Heiman M
    Cell Rep; 2017 Dec; 21(10):2688-2695. PubMed ID: 29212017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.
    Farrar AM; Callahan JW; Abercrombie ED
    Exp Neurol; 2011 Dec; 232(2):119-25. PubMed ID: 21864528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.
    Bissonnette S; Vaillancourt M; Hébert SS; Drolet G; Samadi P
    PLoS One; 2013; 8(9):e75099. PubMed ID: 24040390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.
    Spires TL; Grote HE; Garry S; Cordery PM; Van Dellen A; Blakemore C; Hannan AJ
    Eur J Neurosci; 2004 May; 19(10):2799-807. PubMed ID: 15147313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
    Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
    J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
    Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
    Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
    Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
    J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology.
    Savage JC; St-Pierre MK; Carrier M; El Hajj H; Novak SW; Sanchez MG; Cicchetti F; Tremblay MÈ
    J Neuroinflammation; 2020 Apr; 17(1):98. PubMed ID: 32241286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
    Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
    Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
    MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM
    J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
    Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
    Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice.
    Dickson E; Soylu-Kucharz R; Petersén Å; Björkqvist M
    Mol Metab; 2022 Mar; 57():101439. PubMed ID: 35007790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise training normalizes mitochondrial respiratory capacity within the striatum of the R6/1 model of Huntington's disease.
    Herbst EA; Holloway GP
    Neuroscience; 2015 Sep; 303():515-23. PubMed ID: 26186895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The absence of the aryl hydrocarbon receptor in the R6/1 transgenic mouse model of Huntington's disease improves the neurological phenotype.
    Angeles-López QD; García-Lara L; Aguirre-Pineda N; Castañeda-Arellano R; Elizondo-Azuela G; Pérez-Severiano F; Segovia J
    Behav Brain Res; 2021 Jun; 408():113230. PubMed ID: 33684424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in striatal activity and functional connectivity in a mouse model of Huntington's disease.
    Cabanas M; Bassil F; Mons N; Garret M; Cho YH
    PLoS One; 2017; 12(9):e0184580. PubMed ID: 28934250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.